Retinoic acid induces leukemia cell G1 arrest and transition into differentiation by inhibiting cyclin-dependent kinase-activating kinase binding and phosphorylation of PML/RARalpha

FASEB J. 2006 Oct;20(12):2142-4. doi: 10.1096/fj.06-5900fje. Epub 2006 Aug 25.

Abstract

Acute promyelocytic leukemia (APL) cells express promyelocytic leukemia/retinoic acid receptor alpha (PML/RARalpha) fusion protein, which leads to the blocking of APL cell differentiation. Treatment of APL with all-trans-retinoic acid (ATRA) induces disease remission by in vivo differentiation of APL cells. Differentiation requires cell cycle exit; yet how ATRA couples cell cycle exit to differentiation of APL remains largely unknown. We previously found that ATRA-induced cell differentiation accompanies ubiquitination-proteolysis of ménage à trois 1 (MAT1), an assembly factor and targeting subunit of cyclin-dependent kinase (CDK)-activating kinase (CAK) that regulates G1 exit. We report here that CAK binds to and phosphorylates PML/RARalpha in actively proliferating APL cells. In response to ATRA, PML/RARalpha is dissociated from CAK, leading to MAT1 degradation, G1 arrest, and decreased CAK phosphorylation of PML/RARalpha. CAK phosphorylation of PML/RARalpha is inhibited when MAT1 levels are reduced. Both MAT1 degradation and PML/RARalpha hypophosphorylation occur in ATRA-induced G1-arresting cells undergoing differentiation but not in the synchronized G1 cells that do not differentiate. These findings reveal a novel ATRA signaling on APL cell differentiation, in which ATRA coordinates G1 arrest and transition into differentiation by inducing MAT1 degradation and PML/RARalpha hypophosphorylation through disrupting PML/RARalpha binding and phosphorylation by CAK.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Carrier Proteins / metabolism*
  • Cell Cycle Proteins
  • Cell Differentiation / drug effects*
  • Cell Line, Tumor
  • Cyclin-Dependent Kinase-Activating Kinase
  • Cyclin-Dependent Kinases / antagonists & inhibitors*
  • Cyclin-Dependent Kinases / metabolism
  • G1 Phase / drug effects*
  • Humans
  • Leukemia / pathology*
  • Oncogene Proteins, Fusion / drug effects
  • Oncogene Proteins, Fusion / metabolism*
  • Peptide Hydrolases / metabolism
  • Phosphorylation / drug effects
  • Protein Binding / drug effects
  • Transcription Factors
  • Tretinoin / pharmacology*
  • Ubiquitin / metabolism

Substances

  • Carrier Proteins
  • Cell Cycle Proteins
  • MNAT1 protein, human
  • Oncogene Proteins, Fusion
  • Transcription Factors
  • Ubiquitin
  • promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
  • Tretinoin
  • Cyclin-Dependent Kinases
  • Peptide Hydrolases
  • Cyclin-Dependent Kinase-Activating Kinase